Last reviewed · How we verify
Xinnaoning Capsule
Xinnaoning Capsule, marketed by Beijing Duheng for Drug Evaluation and Research Co., Ltd. (DDER), holds a position in the pharmaceutical market with its key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, though specific revenue figures are not provided. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Xinnaoning Capsule |
|---|---|
| Also known as | Xinnaoning |
| Sponsor | Beijing Duheng for Drug Evaluation and Research Co., Ltd. (DDER) |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: